Pharmaceuticals

Annexon is poised for a landmark year with potential first-in-class drugs for GBS and GA, promising to reset treatment standards and offer new hope.

With pivotal cancer drug data looming and a new nuclear supply chain, Bicycle Therapeutics is betting big on its novel platform. Will 2026 be its breakout year?

With a key FDA filing and pivotal data on the horizon, Pharvaris aims to redefine HAE treatment with its convenient, rapid-acting oral therapy.

Recent findings of bacteria and heavy metals in baby formula have parents worried and legal experts demanding greater manufacturer accountability.

With booming revenue, a potential blockbuster on the horizon, and key partnerships, Ascendis Pharma lays out a bold roadmap for global dominance.

With drug costs soaring, industry veteran Ritu Malhotra joins Illuminate Rx, promising to disrupt the opaque PBM market. But can transparency truly win?

After a decade of research, a promising drug for Fragile X syndrome enters a key trial, offering hope for the first-ever targeted treatment for the disorder.

Beyond a simple time change, Fortrea's upcoming JPM presentation is a critical test for its new CEO and a key moment to define its future in the CRO market.

A novel drug that glues cancer proteins to the cellular trash system has entered human trials, offering new hope for rare diseases like Ewing sarcoma.

Biotech firm Bright Minds Biosciences closes a massive $175M deal, fueling its race to develop novel drugs for epilepsy and rare neurological conditions.

A new partnership aims to move AI from costly experiments to real-world value in biopharma, combining specialized agents with strategic implementation.

Promising Phase 2 data shows a new DNA immunotherapy for advanced melanoma, delivered via a needle-free jet injector, significantly improves patient outcomes.

As part of a $23B US investment, Novartis will build a cutting-edge facility in Winter Park, cementing Florida’s role in advanced cancer treatment.

A new alliance aims to advance KFRX06, a unique Parkinson's therapy that goes beyond a single target to potentially offer a more comprehensive treatment.

Amazon Pharmacy now offers the new Wegovy pill with transparent cash-pay options, shaking up the high-demand weight management drug market.

With a new board appointment and $19M in funding, Enhanced Genomics is leveraging its 3D genomics platform to build its own pipeline of precision therapies.

Automated Industrial Robotics Inc. acquires Ireland's KAON Automation, a strategic move to dominate the high-stakes medical and life sciences market.

After resolving manufacturing hurdles, Camurus' self-administered acromegaly treatment Oclaiz is back on track for US approval, promising new hope for patients.

Prescient's acquisition of Uptake creates an integrated giant in healthcare consulting. What does this mean for the industry, clients, and patient outcomes?

Akari Therapeutics is advancing a new class of cancer drugs. Its unique PH1 payload kills tumors and activates the immune system, setting up a pivotal 2026.